Abstract:SESSION TITLE: Chest Infections Posters 10 SESSION TYPE: Original Investigation Posters PRESENTED ON: 10/11/2023 12:00 pm - 12:45 pm PURPOSE: Mycobacterium avium complex lung disease (MACLD) is a serious pulmonary infection that can cause lung damage. Patients with refractory MACLD often still test positive for MAC infection after 6 months on guideline-based therapy. There are limited data on treatment patterns and healthcare resource utilization (HCRU) among patients with refractory MACLD in the US. The objective of this study was to assess HCRU among US patients with potentially refractory MACLD treatment patterns. METHODS: A retrospective study was conducted using managed care claims from the IBM® MarketScan® research database (2014.07-2020.06). Treated MACLD patients were those who received diagnosis and subsequent initial therapy of ≥28 days of concurrent macrolide with at least one other antibiotic (ethambutol, rifamycin, aminoglycoside, fluoroquinolone, oxazolidinone, diarylquinoline). The first 6 months of treatment was defined as the baseline regimen and the possible refractory date was the date 6 months after treatment initiation. Among patients treated for ≥18 months, treatment patterns indicating potentially refractory MACLD were defined as adding new drug classes after the 6-month baseline treatment. The proportion of refractory MACLD patients with hospitalizations (all-cause, respiratory-related, and NTMLD-related) was assessed at 6-month intervals for a total of 2 years after treatment initiation. RESULTS: The study identified 87 patients (7.5% of 1164 patients treated for MACLD) who showed potentially refractory treatment patterns during the 12-month period after the possible refractory date. Mean (SD) age at MACLD diagnosis was 62 (13) years; 70% were female. During the baseline period, 16% had gastroesophageal reflux disease; common pulmonary comorbidities included COPD (32%), bronchiectasis (29%), pneumonia (29%) and asthma (21%). All-cause and respiratory-related hospitalization rates were high (17% and 7%) during the 6-month baseline treatment period and continued to increase over the 2-year follow-up period, reaching 22% and 11% in months 19-24 after treatment initiation despite treatment of at least 18 months. Ethambutol and rifamycin were included in the baseline regimens of 85% and 82% of refractory patients, respectively. Fluoroquinolone was the most commonly added drug (by 77% of patients) in the 12-month post-refractory treatment period, followed by aminoglycoside (9%). CONCLUSIONS: Despite treatment of at least 1.5 years, patients with potentially refractory MACLD showed high hospitalization burden which remained high or increased over a 2-year follow-up period after treatment initiation. CLINICAL IMPLICATIONS: The increase in hospitalization burden observed after the 6-month initial treatment highlights the need for treatment monitoring and improved management among patients with refractory MACLD. DISCLOSURES: Employee relationship with Insmed Pharmaceuticals Please note: 4 years Added 03/24/2023 by Mariam Hassan, source=Web Response, value=Salary No relevant relationships by Matthew Lucci No relevant relationships by Bonny Shah Employee relationship with Insmed Incorporated Please note: Mar 2017 to Present by Ping Wang, value=Salary Employee relationship with Insmed Incorporated Please note: Mar 2017 to Present Added 03/23/2023 by Ping Wang, source=Web Response, value=Stocks No relevant relationships by Emily Welch Research relationship with Insmed Please note: 24 months or more by Kevin Winthrop, value=Consultation fees Research relationship with Paratek Please note: 24 months or more by Kevin Winthrop, value=Consulting fees Research relationship with Redhill Biopharma Please note: 24 months or more by Kevin Winthrop, value=Consultation fees Research relationship with AN2 Please note: 24 months or more by Kevin Winthrop, value=Grant/Research Support Consultant relationship with AN2 Please note: 24 months or more by Kevin Winthrop, value=Consulting fee Consultant relationship with Spero Therapeutics Please note: 24 months or more by Kevin Winthrop, value=Consulting fee

Amikacin Liposome Inhalation Suspension As a Treatment for Patients with Refractory Mycobacterium Avium Complex Lung Infection

Amikacin Liposomal Inhalation Suspension for Non-Tuberculous Mycobacteria Lung Infection: A Greek Observational Study

Effectiveness of Amikacin liposome inhalation suspension for refractory Mycobacterium avium complex pulmonary disease at 6 months post initiation

Amikacin Liposomal Inhalation Suspension in the Treatment of Mycobacterium abscessus Lung Infection: A French Observational Experience

Ceftazidime/Avibactam versus Polymyxin B in the Challenge of Carbapenem-Resistant <i>Pseudomonas</i> aeruginosa Infection

Aerosolized Amikacin As Adjunctive Therapy of Ventilator-Associated Pneumonia Caused by Multidrug-Resistant Gram-Negative Bacteria: A Single-Center Randomized Controlled Trial

The use of dual β-lactams to restore susceptibility of Mycobacterium avium complex

The Clinical and Microbiological Utility of Inhaled Aztreonam Lysine for the Treatment of Acute Pulmonary Exacerbations of Cystic Fibrosis: an Open-Label Randomised Crossover Study (AZTEC-CF).

In Vitro Assessment of 17 Antimicrobial Agents Against Clinical Mycobacterium Avium Complex Isolates

Safety and Efficacy of Clofazimine as an Alternative for Rifampicin in Mycobacterium avium Complex Pulmonary Disease Treatment: Outcomes of a Randomized Trial

Intravenous combined with aerosolised polymyxin versus intravenous polymyxin alone in the treatment of pneumonia caused by multidrug-resistant pathogens: a systematic review and meta-analysis

Ceftriaxone Efficacy for Mycobacterium avium Complex Lung Disease in the Hollow Fiber and Translation to Sustained Sputum Culture Conversion in Patients

Antibacterial action of penicillin against Mycobacterium avium complex

In vitro killing of drug susceptible and multidrug resistant bacteria by amikacin considering pulmonary drug concentrations based on an inhaled formulation

1866. Can β-lactam Combinations Restore Susceptibility Against Mycobacterium avium Complex: Exploring a New Approach to a “Difficult to Treat” Opportunistic Pathogen

Treatment patterns and health care resource utilization among patients with potentially treatment-refractory mycobacterium avium complex lung disease in the united states

Inhaled immunoantimicrobials for the treatment of chronic obstructive pulmonary disease

Treatment outcomes for Mycobacterium avium complex: a systematic review and meta-analysis

Regimen comprising clarithromycin, clofazimine and bedaquiline is more efficacious than monotherapy in a mouse model of chronic lung infection

Polymyxin B Plus Aerosolized Colistin vs Polymyxin B Alone in Hospital-acquired Pneumonia ("AEROCOL" Study): A Feasibility Study

Moxifloxacin monotherapy versus combination therapy in patients with severe community-acquired pneumonia evoked ARDS